A big woof from your favourite interspecies team!

Wins

Our paper went live in the Journal of Clinical Oncology (JCO) at the end of April. JCO is the leading global oncology journal that clinicians around the world read to update their practice. JCO commissioned an exclusive editorial to highlight our paper (reserved for 5% of articles) and invited us to their podcast (1/month) to discuss our results of 90%+ accuracy in detecting 20 types of cancers from breath, including 90%+ sensitivity at Stage-1.

Following the publication, as well as announcement of being part of Accel India and Prosus' AtomsX, Dognosis received a ton of organic press from BBC News, Bloomberg, WION, NDTV Profit, CNBC-TV18, Times of India, India Today, Business Standard, Hindustan Times, TechCrunch, YourStory, Inc42, Startuppedia, Indian Express, STAT, Happier Health and many more. Some highlights:

• Rahul, co-founder of the premier Indian long-form media-house Tigerfeathers wrote a wonderful piece on our story and vision, and Caleb did a great in-depth video at Runtime BRT
• Sadhguru, the global icon with millions of followers, spoke about us in one of his weekly talks
• Packy from Not Boring covered us in a Weekly Dose of Optimism
• We were invited to give a talk and panel, and be part of a documentary at AI4.co, America's largest AI conference
• Various accounts across Instagram, LinkedIn, X, and WhatsApp made organic content (idkshowdaily, tech creator, 100xengineers) covering our work, aggregating over 1M views, and leading to more than 5000 new followers and 200k impressions on our socials.

This press and public interest translated to over 500 inbound leads for people interested in taking our test. We've done dozens of lengthy calls with these leads, generating rich insights on who our early adopters are, who include:

• People with family/personal history of cancer
• 20-30 year-olds who are interested in purchasing our test for their parents
• Dog-lovers who say they want to do our test specifically because they love our mission and how we're unleashing the superpowers of dogs

The insight from these calls changed our plans. We're now going straight to people instead of only through hospitals, starting with our BreathEasy launch in Bangalore in January 2027.

We're onboarding top global cancer detection researchers and clinicians to our scientific and trial advisory board and we're formalizing collaborations with leading global clinical institutes, more to come out soon.

Our team has only gotten stronger, with Sagar (India GTM Lead), Susmita (Regulatory Lead), Manal (Comms Lead), Madhu (Senior Data Scientist), Christy (People and Office Ops Manager), Mamatha (Lab Technician), Hari (Office Admin), Samarth (Associate Founders Office) and David (SWE with 4yrs of experience) joining the Pack, along with our friendly canine AI agent Lucky.

We're hiring for multiple roles, including a Medical Affairs Lead (Doctor x Product), a Brand Marketer, Founding Designer, and a Head of Finance/Ops. We'd also love to hear from current or former founders and marketers with real experience building a D2C brand, and from people who understand how clinical imaging chains work, their incentives and structures, so we can build strong partnerships ahead of our commercial launch.

R&D

SniffSpace V2 is officially in production. After months of design, prototyping, and testing, all our dogs have now moved fully onto V2 from V1, and production has a way of surfacing what got missed in development. We caught and fixed bugs across mechanical, electrical, and software-hardware integration, closed some safety gaps, and improved reliability, all without taking the platform offline. V2 brings automated sample presentation, real-time sample ID, sniff detection, localized VOC clearing between samples, and a vision-model-based reward system that automates another piece of the training loop. Overall, V2 has the capacity to improve our throughput to 288 sniffs-per-dog-hour. Next up: hardening the platform for scale, and preparing to deploy SniffSpace V2 to MDD (Medical Detection Dogs), our UK collaborator.

Our science team spent time stress-testing everything that could throw off a result before it ever reaches our dogs: different hospitals, different storage conditions, different collection settings, even a patient's own stress levels. Alongside that, we tightened how the lab runs day to day, and started weaving in new signals, like a dog's breathing and brain activity, to make every report stronger.

Plans

Q3 is focused on bringing our systems to production-grade stability, executing on-going trials to generate case-studies of detecting undiagnosed cancers, and continuing to build our GTM, Marketing, and Medical Affairs functions. We'll also aim to finalize our follow-up protocol, secure 2 partnerships with imaging chains with a great user experience, and have over a 1000 people on our product waitlist.

Parting Barks

This has been the busiest things have ever been. The team has needed to execute on multiple fronts with a large amount of context-switching in a given day, time-frame shifting in every week, and dealing with all the growing pains of being a large organization with mounting stakers and complexity. It's been helpful to have clear North Star goals for the remainder of this year:

• 1,000 samples a week by October,
• 5 undiagnosed early-stage cancers detected by December,

And of course, no matter how challenging it gets, both of us know we would never choose another timeline where we were not giving it our all to build Dognosis.

Dogspeed,
Akash and Itamar
The Dognosis Pack